Boston Scientific DBS Systems Detail Indications, Contraindications and Safety Warnings

Boston Scientific Outlines Clear System Indications and Safety Guidelines for Deep Brain Stimulation Therapies

Patients considering movement disorder treatments now face a precise set of clinical boundaries, as outlined in technical documentation from medical device manufacturer Boston Scientific. The company details specific approval criteria for its Vercise PC, Vercise Gevia, and Vercise Genus Deep Brain Stimulation systems, delineating exactly which neurological conditions qualify for the adjunctive therapies and which patient profiles face strict contraindications.

Under the outlined indications, bilateral stimulation of the subthalamic nucleus and the internal globus pallidus serves as an adjunctive therapy to reduce moderate to advanced levodopa-responsive Parkinson’s disease symptoms that defy adequate medication control. For tremor suppression in the upper extremity, unilateral or bilateral thalamic stimulation of the ventral intermediate nucleus targets essential tremor or parkinsonian tremor that creates significant functional disability despite pharmacological intervention.

Implanted Hardware Restricts Magnetic Resonance Imaging Exposure

The documentation establishes rigid safety parameters regarding medical imaging and physical treatments for individuals implanted with the hardware. Patients carrying Boston Scientific DBS systems without ImageReady MRI Technology face a strict ban on magnetic resonance imaging exposure.

Those with specific qualifying setups—such as the Vercise Gevia, Vercise Genus, or Vercise Genus Mixed System with M8 Adapter, along with lead-only configurations—gain full body MR conditional status only under exact guidelines. Meanwhile, external components like the charging system, remote control, and mobile controller remain strictly MR unsafe and must stay outside any magnetic resonance environment.

Further medical procedure restrictions prohibit diathermy treatments, whether used therapeutically or during surgery, alongside electroconvulsive therapy and transcranial magnetic stimulation. The safety of these modalities remains unestablished for implanted individuals.

Daily Routines Demand Strict Adherence to Safety Protocols

Operating the Vercise hardware requires careful adherence to daily safety protocols. The technical guidance warns against charging the stimulator while sleeping and advises users to avoid high stimulation levels that risk damaging brain tissue. Strong electromagnetic fields generated by power generators, security screeners, or retail theft detection systems can inadvertently shut down the stimulator or trigger erratic output changes.

Physical hazards extend to daily routines. The manufacturer stresses that chemical burns may occur if the stimulator housing becomes ruptured or pierced. The DBS architecture can interfere with concurrent cardiac pacemakers, implantable cardioverter defibrillators, or medication delivery pumps.

Patients must maintain caution when engaging in activities requiring coordination, such as swimming, or when operating motorized vehicles and heavy machinery. The guidelines also flag the necessity of immediate medical contact should users experience new or worsening depression, behavioral shifts, impulse control issues, or thoughts of suicide.

The company notes that pregnancy complications related to the device remain unknown. Federal law in the United States restricts these medical devices to sale by or on the order of a physician, and patients are urged to consult medical professionals to review individual risks and benefits.